Log in to search using one of your social media accounts:

 

Get Active, Beat Lymphoma?
Title: Get Active, Beat Lymphoma?Category: Health NewsCreated: 12/12/2017 12:00:00 AMLast Editorial Review: 12/13/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 13, 2017 Category: Cancer & Oncology Source Type: news

Get Active, Beat Lymphoma?
That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. (Source: WebMD Health)
Source: WebMD Health - December 12, 2017 Category: Consumer Health News Source Type: news

Get Active, Beat Lymphoma?
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2017 Category: Cancer & Oncology Tags: Oncology, Sports Medicine, News, Source Type: news

Get Active, Beat Lymphoma?
TUESDAY, Dec. 12, 2017 -- Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 12, 2017 Category: General Medicine Source Type: news

Researchers develop test that can diagnose two cancer types
(Georgia State University) A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: news

First in 30 Years: Improved Front Line in Hodgkin's Lymphoma First in 30 Years: Improved Front Line in Hodgkin's Lymphoma
Brentuximab vedotin has already made an impact on the management of relapsed/refractory classical Hodgkin's lymphoma. Now the drug is poised for frontline use.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive
New longer-term data on CAR T cells in patients with refractory and relapsed (R/R) lymphoma show that responses are durable, with about half of patients alive after a year or more.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH: Anti - CD19 CAR T - Cell Tx Beneficial in B - Cell Lymphomas
Second study shows benefit in relapsed or refractory B - cell lymphoma, follicular lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: A + AVD Beats ABVD for Advanced Hodgkin ’ s Lymphoma
Lower combined risk of progression, death, or noncomplete response with A + AVD (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Rhizen receives USFDA fast track designation for cancer drug
USFDA has granted Fast Track Designation for RP6530.. for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL)," Alembic Pharmaceuticals said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 11, 2017 Category: Pharmaceuticals Source Type: news

CAR T-cell therapies drive outcomes in lymphoma, myeloma
(American Society of Hematology) For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2017 Category: Cancer & Oncology Source Type: news

Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

How Does Pediatric Sj ö gren Syndrome Present?
Discussion Sjögren Syndrome (SS) is named for Swedish ophthalmologist Henrik Sjögren who published a case series in 1933 describing patients with dry eyes and arthritis. SS is a “chronic autoimmune inflammatory exocrinopathy” that is characterized by lymphocytic infiltration of the lacrimal and salivary glands and has various degrees of systematic involvement. Keratoconjunctivitis sicca and xerostomia are the main clinical symptoms. Sicca is a Latin word meaning dry. Dryness of the eyes and mouth without evidence of autoimmune disease is called Sicca syndrome or Sicca complex. SS can be primary or se...
Source: PediatricEducation.org - December 11, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Gilead's new drug keeps 56 percent of lymphoma trial patients alive
(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis CAR-T therapy leads to durable response in lymphoma study
(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Gilead dispels doubts with Car-T cancer drug trial results
Study shows lymphoma patients live longer after pioneering cell therapy (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 10, 2017 Category: Pharmaceuticals Source Type: news

Roche lymphoma drug drives high remission rate, longer survival: study
(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - December 10, 2017 Category: Pharmaceuticals Source Type: news

Phase II data showed Roche ’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma
Roche today announced positive results from the randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera ®/Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2017 Category: Pharmaceuticals Source Type: news

Global CAR T therapy trial shows high rates of durable remission for NHL
(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah ™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577). Results from the single-site study, with follow-up extending past two years, will be published today in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

Phase 2 CAR-T study reports significant remission rates at 15-month follow up
(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta ™ ). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3 ½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 10, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Huntington's disease: Could a cancer drug hold the key?
A drug that is used to treat advanced skin lymphomas may also be effective in treating Huntington's disease and other neurodegenerative diseases. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 8, 2017 Category: Consumer Health News Tags: Huntington's Disease Source Type: news

Leukemia & Lymphoma Society awards $1.7 million in local grants
The Leukemia& Lymphoma Society is awarding more than $1.7 million grants in St. Louis to blood cancer research efforts. The local grants are part of the organization's broader research commitment of $46 million globally focused on research for blood cancer cures. Local researchers receiving funding from LLS include four Washington University medical school doctors: Dr. Takeshi Egawa, who received a career developm ent program grant; Dr Timothy Ley, who received a translational research program… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 8, 2017 Category: Health Management Authors: Angela Mueller Source Type: news

Leukemia & Lymphoma Society awards $1.7 million in local grants
The Leukemia& Lymphoma Society is awarding more than $1.7 million grants in St. Louis to blood cancer research efforts. The local grants are part of the organization's broader research commitment of $46 million globally focused on research for blood cancer cures. Local researchers receiving funding from LLS include four Washington University medical school doctors: Dr. Takeshi Egawa, who received a career developm ent program grant; Dr Timothy Ley, who received a translational research program… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 8, 2017 Category: Biotechnology Authors: Angela Mueller Source Type: news

Sanofi explores combination treatments for multiple myeloma in new late-stage trials
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia. (Source: World Pharma News)
Source: World Pharma News - December 7, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Minimizing Bacteria Around Macrotextured Breast Implants Minimizing Bacteria Around Macrotextured Breast Implants
Find out how to reduce the number of bacteria around macrotextured breast implants to prevent the incidence of implant-associated anaplastic large-cell lymphoma.Plastic and Reconstructive Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2017 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial clinical hold lifted
Roche today announced that following close consultation and agreement on study modifications with the U.S. Food and Drug Administration (FDA), the partial clinical holds placed on the Phase Ib and Phase Ib/II studies evaluating TECENTRIQ in combination with an immunomodulatory medicine (IMiD) in relapsed/refractory multiple myeloma and relapsed/refractory follicular lymphoma have been lifted. (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2017 Category: Pharmaceuticals Source Type: news

Shut-off switch for lymphoma
(Technical University of Munich (TUM)) Safety switches that automatically stop the device for example before it overheats are built into many electrical appliances. Cells are also equipped with such 'emergency stop' functions. They make sure that a defective cell doesn't become a tumor cell. A team from Technical University of Munich has now discovered such a switch in T cells. These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2017 Category: Cancer & Oncology Source Type: news

Flight attendant battling two cancers gets the all clear
Doaa Abouelseoud, from Cairo, Egypt, battled stage three breast cancer and rare Hodgkin Lymphoma. She says the ordeal has given her a completely new positive outlook on life. (Source: the Mail online | Health)
Source: the Mail online | Health - December 4, 2017 Category: Consumer Health News Source Type: news

Genetic link found between the immune system and lymphoma
(Institute of Cancer Research) People who inherit genetic changes which alter the function of their immune system are at increased risk of developing Hodgkin lymphoma, a major new study reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2017 Category: Cancer & Oncology Source Type: news

Immune-boosting antibody combination could improve lymphoma survival
(Cancer Research UK) Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell today (Thursday). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2017 Category: Cancer & Oncology Source Type: news

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas
Activation of the RAS-RAF-MEK-ERK signaling pathway is implicated in driving the initiation and progression of multiple cancers. Several inhibitors targeting the RAS-MAPK pathway are clinically approved as single- or polyagent therapies for patients with specific types of cancer. One example is the MEK inhibitor trametinib, which is included as a rational polytherapy strategy for treating EML4-ALK–positive, EGFR-activated, or KRAS-mutant lung cancers and neuroblastomas that also contain activating mutations in the RAS-MAPK pathway. In addition, in neuroblastoma, a heterogeneous disease, relapse cases display an incre...
Source: Signal Transduction Knowledge Environment - November 28, 2017 Category: Science Authors: Umapathy, G., Guan, J., Gustafsson, D. E., Javanmardi, N., Cervantes-Madrid, D., Djos, A., Martinsson, T., Palmer, R. H., Hallberg, B. Tags: STKE Research Articles Source Type: news

Health Canada finds low number of rare cancer cases linked to breast implants
Health officials aren't recommending people have their breast implants removed after the Canadian government released its safety review on cases of implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Source: CBC | Health)
Source: CBC | Health - November 24, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

GST makes ‘orphan drugs’ prices soar
These high-value ‘orphan’ drugs used in bone marrow transplant, classical Hodgkin Lymphoma, Crohn’s disease and melanoma. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Bone marrow cancer: What you need to know
In this article, learn about the types of bone marrow cancer, including multiple myeloma, leukemia, and lymphomas. How are they diagnosed and treated? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 22, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Researchers show stress suppresses response to cancer treatments
(University of Queensland) New research shows that chronic stress suppresses the immune system's response to cancer, reducing the effectiveness of immunotherapy treatments.University of Queensland scientists say they are investigating dual therapies for patients to reduce stress signalling and improve their response to treatments.UQ Diamantina Institute researcher Dr. Stephen Mattarollo said lymphoma progressed more rapidly in mouse models when stress pathways were induced to reflect chronic psychological stress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2017 Category: Cancer & Oncology Source Type: news

The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research
(UNC Lineberger Comprehensive Cancer Center) A grant from The Leukemia& Lymphoma Society will help fund clinical research led by UNC Lineberger's Barbara Savoldo, MD, PhD, into an investigational chimeric antigen receptor (CAR) T-cell treatment for acute lymphoblastic leukemia that would include a built-in 'safety switch.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 21, 2017 Category: Cancer & Oncology Source Type: news

Three UCLA professors named fellows of the American Association for the Advancement of Science
Two  doctors and a dentist from UCLA have been selected as 2017 fellows of the American Association for the Advancement of Science. They are among 396 members awarded this honor by the AAAS for their scientifically or socially distinguished efforts to advance science or its applications.New fellows will be presented with an official certificate and a gold and blue rosette pin, representing science and engineering, on Feb. 17, 2018, at the association ’s annual meeting in Austin, Texas, and formally announced in the “AAAS News and Notes” section of the journal Science on Nov. 24.UCLA ’...
Source: UCLA Newsroom: Health Sciences - November 20, 2017 Category: Universities & Medical Training Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Media News - November 17, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Gazyva for previously untreated advanced follicular lymphoma
Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva ® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The approval is based on results from the phase III GALLIUM study, which showed superior progression-fre e survival (PFS) for patients who received this Gazyva-based regimen compared with those who received a Rituxan® (rituximab)-based regimen as an initial (first-line) therapy. Follicular lymphoma, the most common slow-growing (indolent) f...
Source: Roche Investor Update - November 17, 2017 Category: Pharmaceuticals Source Type: news

ALEX study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients
(European Society for Medical Oncology) A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2017 Category: Cancer & Oncology Source Type: news

FDA backs Roche's Gazyva in first-line follicular lymphoma
ZURICH (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

HBV Infection and Development of Non-hodgkin Lymphoma HBV Infection and Development of Non-hodgkin Lymphoma
This study investigated the association of HBV infection and risk of non-Hodgkin's lymphoma. Might HBV vaccination reduce the risk in certain populations?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 16, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

FDA Approves Genentech ’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
South San Francisco, CA -- November 16, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) in combination with chemotherapy,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2017 Category: Drugs & Pharmacology Source Type: news

Targeting cancer without destroying healthy T-cells
(Cardiff University) A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the aggressive and difficult-to-treat family of cancers, finds a study involving researchers from Cardiff University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 15, 2017 Category: Cancer & Oncology Source Type: news

New lymphoma treatment developed at Cardiff University
Researchers find a method to kill cancerous cells without destroying healthy cells. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 14, 2017 Category: Consumer Health News Source Type: news

FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Anti-TNF Agents, Thiopurines Increase Lymphoma Risk in IBD Anti-TNF Agents, Thiopurines Increase Lymphoma Risk in IBD
Thiopurines and anti-TNF agents were associated with a small but significant increase in the risk for lymphoma in patients with IBD, particularly when used in combination, a study has found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news